Linifanib

Key Product Details

Product Description

Linifanib is a potent receptor tyrosine kinase (RTK) inhibitor. It inhibits PDGFRβ, KDR, FLT3, CSF-1R (IC₅₀ values are 2, 4, 4 and 7 nM, respectively). Linifanib inhibits angiogenesis in vascularized micro-organs and potently inhibits VEGF-stimulated endothelial cell proliferation (IC₅₀ = 0.2 nM). Linifanib also promotes the generation and reprogramming of iPSCs from somatic cells.

Product Specifications for Linifanib

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Linifanib

The following data is based on the product molecular weight 375.40.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

4 3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.66 mL	13.32 mL	26.64 mL
5 mM	0.53 mL	2.66 mL	5.33 mL
10 mM	0.27 mL	1.33 mL	2.66 mL
50 mM	0.05 mL	0.27 mL	0.53 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Guan Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature 2022 PMID: 35418683
• Jahid Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer. Cell Rep. 2022 PMID: 35385746
• Albert Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol.Cancer Ther. 2006 PMID: 16648571

Product Documents for Linifanib